2 results match your criteria: "" IRCCS Pediatric University-Hospital[Affiliation]"
Prospective follow up after omalizumab discontinuation in a cohort of children with severe asthma.
Pediatr Pulmonol
August 2023
Department of Mother and Child Health, Azienda USL Toscana Nord Ovest, Pisa, Italy.
Severe pediatric asthma therapy: Omalizumab-A systematic review and meta-analysis of efficacy and safety profile.
Front Pediatr
March 2023
Pediatric Pulmonary Unit, "Anna Meyer, " IRCCS Pediatric University-Hospital, Florence, Italy.
Background: Omalizumab is the first biological therapy used to treat moderate-to-severe asthma and certainly the one with the highest number of publications.
Methods: A systematic review and meta-analysis were performed to examine two critical outcomes of omalizumab therapy, asthma exacerbation rate, the reduction of the use of inhaled corticosteroids (ICS), and the improvement of the lung function as a secondary outcome using the following keywords in the MEDLINE database: "anti-IgE, severe asthma, children, and randomized controlled trial." We specifically selected papers that included moderate-to-severe asthma patients and collected data on children and adolescents.